Life Science Investing Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Life Science Investing Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Life Science Investing Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial
